Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT06109272 |
| Title | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) |
| Acronym | LIVIGNO-2 |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | AbbVie |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |